TabletsClinical Overview
Mirabegron Extended-Release Tablets (25mg, 50mg) is a first-in-class, potent and selective beta-3 adrenergic receptor agonist on the WHO Model List framework for Overactive Bladder (OAB). In the urinary bladder, it stimulates beta-3 adrenergic receptors on the detrusor muscle during the urine storage phase, activating adenylyl cyclase and raising cyclic AMP, relaxing detrusor muscle tone and increasing bladder storage capacity without anticholinergic dry mouth, constipation, or cognitive impairment. Indicated for symptomatic treatment of urgency, increased micturition frequency, and urgency incontinence associated with Overactive Bladder.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily, 25 mg to 50 mg with water, with or without food. Swallow the extended-release tablet whole; do NOT crush, divide, or chew. In severe renal impairment (eGFR 15-29 mL/min) or moderate hepatic impairment (Child-Pugh B), do not exceed 25 mg daily.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Hypertension (elevated blood pressure), urinary tract infection, headache, nasopharyngitis, tachycardia. Rare/Severe: Severe hypertensive crisis (BP >= 180/110 mmHg), urinary retention (especially in bladder outlet obstruction), and angioedema.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Regularly monitor blood pressure before initiating and periodically during therapy; strictly contraindicated in severe uncontrolled hypertension (systolic BP >= 180 mmHg and/or diastolic BP >= 110 mmHg). Moderate inhibitor of CYP2D6; increases plasma levels of metoprolol, desipramine, and flecainide.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, nephrological diagnosis, or urological treatment recommendations. Always consult a registered nephrologist, urologist, or qualified medical practitioner before initiating, modifying, or discontinuing any kidney or urinary tract medication.